Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
01 févr. 2022 08h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022
10 janv. 2022 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat...
Skye Bioscience to Present at H.C. Wainwright BIOCONNECT Virtual Conference
04 janv. 2022 08h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat...
Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD
15 déc. 2021 08h30 HE
|
Skye Bioscience, Inc.
Skye Bioscience Announces Promotion of Tu Diep, MSc to Chief Development Officer SAN DIEGO, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the...
Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360
21 oct. 2021 08h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program
12 oct. 2021 13h35 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development
07 oct. 2021 09h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases...
Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer
05 oct. 2021 08h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases...
Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering
29 sept. 2021 16h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Announces $7.0 Million Registered Direct Offering
27 sept. 2021 09h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...